Reltecimod

Description: Reltecimod, a CD28 antigen inhibitor, is used potentially for the treatment of necrotizing soft tissue infection. Smiles: C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@H](C(N[C@@H](C(O)=O)C)=O)CC(O)=O)=O)=O)C)=O)C(C)C)=O)CC(C)C)=O)CCSC)(=O)[C@H]2N(C([C@@H](NC([C@@H](C)N)=O)CO)=O)CCC2. References: Ahn M, Han YH, Park JE, Kim S, Lee WC, Lee SJ, Gunasekaran P, Cheong C, Shin SY Sr, Kim HY, Ryu EK, Murugan RN, Kim NH, Bang JK. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1. J Med Chem. 2015 Jan 8,58(1):294-304. doi: 10.1021/jm501147g. Epub 2014 Nov 5. PubMed PMID: 25347203.